Navigation Links
Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

d of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, manufacturing and marketing FavId or Favrille's other product candidates; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId re
'"/>




Page: 1 2 3

Related medicine technology :

1. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/29/2015)... 2015 In der klinischen Studie ... tägliche Einnahme des L. reuteri ... und die Darmproduktion von Proteinfaktoren verändert, die ... tägliche Einnahme von Nutraceutix, L. reuteri ... der patentierten Verabreichungstechnologie BIO- tract ®, die ...
(Date:7/29/2015)... Commenting on GSK,s Q2 performance, the first ... reveals sales rose during the period and that ... Ahead of a November R&D update day he reiterates ... interview and transcript are available now on http://video.merchantcantos.com ... webcasts with senior company executives. If you would like ...
(Date:7/29/2015)... 2015  Henry Schein, Inc. (NASDAQ: HSIC ... products and services to office-based dental, animal health ... financial results. Net sales for the ... an increase of 0.5% compared with the second ... in local currencies and a 7.0% decline related ...
Breaking Medicine Technology:Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2Henry Schein Reports Record Second Quarter Results 2Henry Schein Reports Record Second Quarter Results 3Henry Schein Reports Record Second Quarter Results 4Henry Schein Reports Record Second Quarter Results 5Henry Schein Reports Record Second Quarter Results 6Henry Schein Reports Record Second Quarter Results 7Henry Schein Reports Record Second Quarter Results 8Henry Schein Reports Record Second Quarter Results 9Henry Schein Reports Record Second Quarter Results 10Henry Schein Reports Record Second Quarter Results 11Henry Schein Reports Record Second Quarter Results 12Henry Schein Reports Record Second Quarter Results 13Henry Schein Reports Record Second Quarter Results 14Henry Schein Reports Record Second Quarter Results 15Henry Schein Reports Record Second Quarter Results 16Henry Schein Reports Record Second Quarter Results 17Henry Schein Reports Record Second Quarter Results 18Henry Schein Reports Record Second Quarter Results 19Henry Schein Reports Record Second Quarter Results 20Henry Schein Reports Record Second Quarter Results 21Henry Schein Reports Record Second Quarter Results 22Henry Schein Reports Record Second Quarter Results 23Henry Schein Reports Record Second Quarter Results 24Henry Schein Reports Record Second Quarter Results 25
(Date:7/29/2015)... ... July 29, 2015 , ... " mybody ” was featured ... small, medium and large businesses making an impact in their industry. Andrew Tropeano, the ... how these advanced probiotic skincare products are designed to strengthen the skin’s defense system ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... ., a global provider of life insurance, annuities, employee benefits and asset management, ... Carolina inclusive sporting event taking place in Charlotte, North Carolina on October ...
(Date:7/29/2015)... Hoffman Estates, IL (PRWEB) , ... July 29, 2015 , ... ... can both benefit from two new products on Mercola.com: a vertical “garden tower” and ... – which can be squeezed into small corners on a porch, balcony, or rooftop ...
(Date:7/29/2015)... ... 2015 , ... One of the world’s leading experts on ... lifesaving impact of removing aluminum from Alzheimer’s disease patients, announced the Children’s ... on a successful pilot study published in The Journal of Alzheimer’s Disease in ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... has launched a chewable version of its EndoMune Jr. probiotic supplement for children ... all-natural supplement that children can enjoy to maintain a healthy balance of beneficial ...
Breaking Medicine News(10 mins):Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3Health News:Mercola.com Introduces NEW Garden Tower and Enhanced Mineral Solution for Healthy Plants 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 2Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 3
... UT Southwestern Medical Center surgeons have removed a ... incision in the bellybutton rather than the traditional four ... operation in North Texas. , It went better than ... surgery, who completed the 80-minute procedure with Dr. J. ...
... Honor US Firefighter Scott Ellis for His Comeback from, Ostomy Surgery, and ... ... Expedition, WASHINGTON, Feb. 27 Scott Ellis, a ... evening at a ceremony in Washington, D.C. Founded in,1984 by former San ...
... Former Arkansas,Governor and Presidential Candidate Mike Huckabee accepted ... Debate to be held on Monday,March 3, 2008. ... the debate which would also include Senator John ... to discussing the issues that are important to ...
... MIAMI, Feb. 27 Novartis and Sony Pictures ... "SER," a breast cancer prevention and early detection ... campaign combines,Novartis, resources and expertise in oncology and ... in their fight against breast cancer.,The campaign is ...
... WASHINGTON, Feb. 27 Today, the U.S. House,Foreign ... of,PEPFAR, the U.S. Global Leadership Against HIV/AIDS, Tuberculosis, ... of Family Research Council, released the,following statement:, ... passing an HIV/AIDS,bill free of troubling provisions contained ...
... The UCLA Department of Family Medicine, with support from the ... Research on Health and Healthcare, a group that will study ... , The network will also mentor and develop a ... disparities. , The new group to ...
Cached Medicine News:Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 2Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 3Health News:Great Comebacks(R) Program Announces 2007 National Award Winner 2Health News:Great Comebacks(R) Program Announces 2007 National Award Winner 3Health News:Great Comebacks(R) Program Announces 2007 National Award Winner 4Health News:Great Comebacks(R) Program Announces 2007 National Award Winner 5Health News:Novartis and Sony Pictures Television International's Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America 2Health News:Novartis and Sony Pictures Television International's Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America 3Health News:Novartis and Sony Pictures Television International's Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America 4Health News:UCLA launches network to study health care disparities affecting minorities 2
... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
... of pure water, Complete, Compact Systems for ... compact S.D.S. Storage and Distribution Systems are ... of purified water produced by Elix or ... of stored water, provide effective protection against ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: